axitinib
Showing 1 - 25 of 101
Renal Cancer, Kidney Cancer, Renal Cell Carcinoma Trial in Aurora (Axitinib, Pembrolizumab)
Not yet recruiting
- Renal Cancer
- +3 more
- Axitinib
- Pembrolizumab
-
Aurora, ColoradoUniversity of Colorado Cancer Center
Jul 24, 2023
Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)
Enrolling by invitation
- Breast Cancer
- +7 more
- Axitinib
-
Dnipro, Ukraine
- +1 more
Jun 17, 2023
Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma Trial in Chengdu (AK104, Axitinib)
Not yet recruiting
- Renal Cell Carcinoma
- +3 more
- AK104
- Axitinib
-
Chengdu, Sichuan, ChinaWest China Hospital
Apr 10, 2023
Metastatic and/or Advanced Renal Cell Carcinoma, Treated With
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas Trial in Miami (Axitinib, Pembrolizumab)
Active, not recruiting
- Alveolar Soft Part Sarcoma
- Soft Tissue Sarcomas
- Axitinib
- Pembrolizumab
-
Miami, FloridaUniversity of Miami
Dec 29, 2022
Axitinib Dose Reduction and Interruption for Adverse Event
Completed
- Renal Cell Carcinoma
- Axitinib
- +2 more
-
New York, New YorkPfizer
Sep 15, 2022
Pheochromocytoma, Paraganglioma Trial in New York (Axitinib)
Recruiting
- Pheochromocytoma
- Paraganglioma
- Axitinib
-
New York, New YorkColumbia University Irving Medical Center
Oct 5, 2022
Kidney Cancer Trial in Houston (Axitinib)
Active, not recruiting
- Kidney Cancer
- Axitinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 2, 2022
Non-clear Renal Cell Carcinoma Trial in Nanjing, Nanning (Toripalimab, Axitinib)
Recruiting
- Non-clear Renal Cell Carcinoma
- Toripalimab
- Axitinib
-
Nanjing, Jiangsu, China
- +1 more
Mar 13, 2023
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),
Recruiting
- Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma Metastatic
- Selenomethionine (SLM)
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics
Sep 19, 2022
Recurrent or Metastatic NPC Trial in Hong Kong (Axitinib, Avelumab)
Recruiting
- Recurrent or Metastatic NPC
- Axitinib
- Avelumab
-
Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital, The C
Jul 18, 2022
Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)
Active, not recruiting
- Renal Cell Carcinoma
- Pembrolizumab
- +2 more
- (no location specified)
Aug 17, 2022
Mucosal Melanoma Trial in New York (Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib)
Recruiting
- Mucosal Melanoma
- Nivolumab and/or Ipilimumab
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 14, 2022
Hepatocellular Carcinoma Trial in Dallas (Axitinib, Avelumab, Bavituximab)
Not yet recruiting
- Hepatocellular Carcinoma
- Axitinib
- +2 more
-
Dallas, TexasThe University of Texas Southwestern Medical Center
Jun 27, 2022
Advanced Clear Cell Renal Cell Carcinoma Trial in Boston (Axitinib, Palbociclib, Avelumab)
Not yet recruiting
- Advanced Clear Cell Renal Cell Carcinoma
- Axitinib
- +2 more
-
Boston, Massachusetts
- +2 more
Jun 27, 2022
Metastatic Renal Cell Carcinoma Trial in Italy (Axitinib, Nivolumab)
Not yet recruiting
- Metastatic Renal Cell Carcinoma
- Axitinib
- Nivolumab
-
Brescia, Italy
- +22 more
Apr 19, 2023
Metastatic Renal Cell Cancer Trial in United States (Axitinib)
Active, not recruiting
- Metastatic Renal Cell Cancer
- Axitinib
-
Duarte, California
- +3 more
Jun 1, 2022
Recurrent ACC, metastaticACC, Unreaectable ACC Trial in Seoul (Axitinib, Observation)
Completed
- Recurrent ACC, metastaticACC, Unreaectable ACC
- Axitinib
- Observation
-
Seoul, Korea, Republic ofDepartment of Internal Medicine, Seoul National University Hospi
Mar 26, 2022
And Use Of Avelumab In Combination With Axitinib For Treatment
Recruiting
- Advanced Renal Cell Carcinoma
- avelumab
- axitinib
-
Sandwich, Kent, United KingdomPfizer Ltd
May 23, 2022